Volnay Therapeutics

Volnay Therapeutics is a biotech company, which is committed to hastening the creation of novel gene and cell medicines. Having worked in drug development for decades, Volnay finds promising therapeutic assets and revolutionary enabling technologies and offers funding and operational know-how to support these initiatives. With an emphasis on capital efficiency, economic viability, and product manufacturing innovation, Volnay hopes to provide substantial value to both investors and patients.

Johannes Fruehauf

President and Co-Founder

1 past transactions

March Biosciences

Series A in 2024
March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. The company's lead asset, MB-105, is a CD5-targeted CAR-T cell therapy currently in Phase 1 trials in patients with refractory T-cell lymphoma and leukemia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.